A Phase 1 trial of OBI-3424

Trial Profile

A Phase 1 trial of OBI-3424

Phase of Trial: Phase I

Latest Information Update: 01 Nov 2017

At a glance

  • Drugs OBI 3424 (Primary)
  • Indications Acute lymphoblastic leukaemia; T cell lymphoma; T-cell leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Nov 2017 New trial record
    • 30 Oct 2017 According to an OBI Pharma media release, the compnay plans to file an Investigational New Drug (IND) application with the U.S. FDA during early 2018 and to initiate this trial during 1H2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top